What is Vertex Pharmaceuticals's subpart f income, net of credits?

Vertex Pharmaceuticals (VRTX) reported subpart f income, net of credits of -0.5% in Q4 2025.

What does subpart f income, net of credits mean?

The net tax effect of foreign subsidiary income subject to U.S. anti-deferral tax rules.

Subpart F income, net of credits

Vertex Pharmaceuticals Subpart F income, net of credits remained flat by 0.0% to -0.5% in Q4 2025 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementIncome Statement

SectionOther

CategoryRisk

SignalLower is better

VolatilityModerate

First reportedQ1 2025

Last reportedQ4 2025Feb 13, 2026

How to read this metric

Changes reflect the net tax cost of operating through specific foreign jurisdictions.

Detailed definition

This represents the net impact of Subpart F income on the effective tax rate, accounting for available foreign tax credi...

Peer comparison

Commonly found in the tax reconciliation notes of global corporations.

Metric ID: other_effective_income_tax_rate_reconciliation_cross_bor_3ef2fd

Historical Data

1 years

	FY'25
Value	-2.1%

Subpart F income, net of credits at Other Companies

GE VernovaGEV View metric

GE VernovaGEV View metric

Willis Towers WatsonWTW View metric

Frequently Asked Questions

What is Vertex Pharmaceuticals's subpart f income, net of credits?: Vertex Pharmaceuticals (VRTX) reported subpart f income, net of credits of -0.5% in Q4 2025.
What does subpart f income, net of credits mean?: The net tax effect of foreign subsidiary income subject to U.S. anti-deferral tax rules.